These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 8425206

  • 1. Adhesion of metastatic, ras-transformed NIH 3T3 cells to osteopontin, fibronectin, and laminin.
    Chambers AF, Hota C, Prince CW.
    Cancer Res; 1993 Feb 01; 53(3):701-6. PubMed ID: 8425206
    [Abstract] [Full Text] [Related]

  • 2. Site-directed mutagenesis of the arginine-glycine-aspartic acid sequence in osteopontin destroys cell adhesion and migration functions.
    Xuan JW, Hota C, Shigeyama Y, D'Errico JA, Somerman MJ, Chambers AF.
    J Cell Biochem; 1995 Apr 01; 57(4):680-90. PubMed ID: 7542253
    [Abstract] [Full Text] [Related]

  • 3. Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA.
    Behrend EI, Craig AM, Wilson SM, Denhardt DT, Chambers AF.
    Cancer Res; 1994 Feb 01; 54(3):832-7. PubMed ID: 8306346
    [Abstract] [Full Text] [Related]

  • 4. Induction of expression of osteopontin (OPN; secreted phosphoprotein) in metastatic, ras-transformed NIH 3T3 cells.
    Chambers AF, Behrend EI, Wilson SM, Denhardt DT.
    Anticancer Res; 1992 Feb 01; 12(1):43-7. PubMed ID: 1567180
    [Abstract] [Full Text] [Related]

  • 5. Recombinant GST-human osteopontin fusion protein is functional in RGD-dependent cell adhesion.
    Xuan JW, Hota C, Chambers AF.
    J Cell Biochem; 1994 Feb 01; 54(2):247-55. PubMed ID: 8175899
    [Abstract] [Full Text] [Related]

  • 6. Osteopontin is required for full expression of the transformed phenotype by the ras oncogene.
    Wu Y, Denhardt DT, Rittling SR.
    Br J Cancer; 2000 Jul 01; 83(2):156-63. PubMed ID: 10901364
    [Abstract] [Full Text] [Related]

  • 7. Altered sialylation of osteopontin prevents its receptor-mediated binding on the surface of oncogenically transformed tsB77 cells.
    Shanmugam V, Chackalaparampil I, Kundu GC, Mukherjee AB, Mukherjee BB.
    Biochemistry; 1997 May 13; 36(19):5729-38. PubMed ID: 9153413
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of Arg-Gly-Asp (RGD)-mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin.
    Bautista DS, Xuan JW, Hota C, Chambers AF, Harris JF.
    J Biol Chem; 1994 Sep 16; 269(37):23280-5. PubMed ID: 8083234
    [Abstract] [Full Text] [Related]

  • 9. Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-RasV12.
    Teramoto H, Castellone MD, Malek RL, Letwin N, Frank B, Gutkind JS, Lee NH.
    Oncogene; 2005 Jan 13; 24(3):489-501. PubMed ID: 15516973
    [Abstract] [Full Text] [Related]

  • 10. Transforming JB6 cells exhibit enhanced integrin-mediated adhesion to osteopontin.
    Chang PL, Chambers AF.
    J Cell Biochem; 2000 Apr 13; 78(1):8-23. PubMed ID: 10797562
    [Abstract] [Full Text] [Related]

  • 11. Non-RGD domains of osteopontin promote cell adhesion without involving alpha v integrins.
    Katagiri YU, Murakami M, Mori K, Iizuka J, Hara T, Tanaka K, Jia WY, Chambers AF, Uede T.
    J Cell Biochem; 1996 Jul 13; 62(1):123-31. PubMed ID: 8836881
    [Abstract] [Full Text] [Related]

  • 12. Adhesive properties of osteopontin: regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain.
    Senger DR, Perruzzi CA, Papadopoulos-Sergiou A, Van de Water L.
    Mol Biol Cell; 1994 May 13; 5(5):565-74. PubMed ID: 7522656
    [Abstract] [Full Text] [Related]

  • 13. Regulation and function of osteopontin in ras-transformed cells.
    Chambers AF.
    Ann N Y Acad Sci; 1995 Apr 21; 760():101-8. PubMed ID: 7785889
    [Abstract] [Full Text] [Related]

  • 14. Increased cell-substrate adhesion accompanies conditional reversion to the normal phenotype in ras-oncogene-transformed NIH-3T3 cells.
    Shumaker DK, Sklar MD, Prochownik EV, Varani J.
    Exp Cell Res; 1994 Oct 21; 214(2):440-6. PubMed ID: 7925639
    [Abstract] [Full Text] [Related]

  • 15. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells.
    Tuck AB, Arsenault DM, O'Malley FP, Hota C, Ling MC, Wilson SM, Chambers AF.
    Oncogene; 1999 Jul 22; 18(29):4237-46. PubMed ID: 10435636
    [Abstract] [Full Text] [Related]

  • 16. Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts.
    Gardner HA, Berse B, Senger DR.
    Oncogene; 1994 Aug 22; 9(8):2321-6. PubMed ID: 8036014
    [Abstract] [Full Text] [Related]

  • 17. Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer.
    Zhu Y, Denhardt DT, Cao H, Sutphin PD, Koong AC, Giaccia AJ, Le QT.
    Oncogene; 2005 Sep 29; 24(43):6555-63. PubMed ID: 16007184
    [Abstract] [Full Text] [Related]

  • 18. Transcriptional regulation of osteopontin and the metastatic phenotype: evidence for a Ras-activated enhancer in the human OPN promoter.
    Denhardt DT, Mistretta D, Chambers AF, Krishna S, Porter JF, Raghuram S, Rittling SR.
    Clin Exp Metastasis; 2003 Sep 29; 20(1):77-84. PubMed ID: 12650610
    [Abstract] [Full Text] [Related]

  • 19. Ras-responsive genes and tumor metastasis.
    Chambers AF, Tuck AB.
    Crit Rev Oncog; 1993 Sep 29; 4(2):95-114. PubMed ID: 8420573
    [Abstract] [Full Text] [Related]

  • 20. Tumor-derived osteopontin is soluble, not matrix associated.
    Rittling SR, Chen Y, Feng F, Wu Y.
    J Biol Chem; 2002 Mar 15; 277(11):9175-82. PubMed ID: 11741994
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.